Impact of Fundamental Diseases on Patients With COVID-19

Yiguang Chen, MD; Tianhua Li, MD; Yongyi Ye, MD; Yongjian Chen, MD; Jun Pan, PhD

ABSTRACT

Objectives: In December 2019, a new type of coronavirus, called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), appeared in Wuhan, China. Serious outbreaks of coronavirus disease 2019 (COVID-19), related to the SARS-CoV-2 virus, have occurred throughout China and the world. Therefore, we intend to shed light on its potential clinical and epidemiological characteristics.

Methods: In this retrospective study, we included 50 confirmed fatal cases of SARS-CoV-2 reported on Chinese official media networks from January 16, 2020, to February 5, 2020. All the cases were confirmed by local qualified medical and health institutions. Specific information has been released through official channels. According to the contents of the reports, we recorded in detail the gender, age, first symptom date, death date, primary symptoms, chronic fundamental diseases, and other data of the patients, and carried out analyses and discussion.

Results: In total, 50 fatal cases were reported: median age was 70 y old, and males were 2.33 times more likely to die than females. The median number of days from the first symptom to death was 13, and that length of time tended to be shorter among people aged 65 and older compared with those younger than 65 (12 days vs 17 days; \(P = 0.046\)). Therefore, the older patients had fewer number of days from the first symptom to death (\(r = -0.40; P = 0.012\)).

Conclusions: In our study, we found that most of the deaths were elderly men with chronic fundamental diseases, and their COVID-19 progression to death time was shorter. At the same time, we demonstrated that older men are more likely to become infected with COVID-19, and the risk of death is positively correlated with age.

Key Words: COVID-19, SARS-CoV-2, The elderly

Since December 2019, an infectious disease, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has spread from Wuhan to other parts of China, also to other countries. On February 11, 2020, the World Health Organization (WHO) named the disease caused by SARS-CoV-2 as “coronavirus disease 2019” or “COVID-19.” In the early stages of the disease, patients show severe acute respiratory infection symptoms. Some patients rapidly develop acute respiratory distress syndrome (ARDS), acute respiratory failure, and even die. Although the Chinese government has blockaded Wuhan, the number of infections and deaths continues to rise. Doctor Wenliang Li, named “Sentinel” by the Chinese people, also unfortunately died of this infectious disease. The statistics are not only numbers, they also represent suffering lives.

Like severe acute respiratory syndrome (SARS) and middle east respiratory syndrome (MERS), COVID-19 also is characterized by flu-like symptoms, including fever, cough, and anhelation, and has the possibility of transmission from animals to humans. At the time of this writing, compared with the other two viruses, the SARS-CoV-2 has relatively mild symptoms and low mortality, but is more contagious.

We have collected relevant information about 50 deaths confirmed to have been caused by COVID-19 and made some new analyses to improve the understanding of the disease.

METHODS

Data Sources and Searches

In this retrospective study, we collected data from official Chinese websites and news sources and also included demographic information about each death from January 16, 2020, to February 5, 2020. We acquired data published on January 16, 2020; January 21, 2020; January 23, 2020; January 25, 2020; January 27, 2020; January 30, 2020; February 2, 2020; February 5, 2020. Our research has passed the review of the ethics committee of Southern Medical University.
Statistics
We apply median values to describe the difference between two groups, and correlation coefficients to describe the correlation between two indicators. Wilcoxon tests were performed for univariate analyses. Excel was used for data input and collation, and R software version 3.6.0 and MedCalc 15.0 were used for descriptive analyses and statistical analyses. A \( P < 0.05 \) was considered to be statistically significant.

RESULTS
Basic Characteristics of Cases
From January 9, 2020, to February 4, 2020, a total of 50 deaths caused by infection with the new coronavirus pneumonia were reported: 35 males and 15 females. The gender ratio of male to female was 2.33:1. The age span of the patients was between 36 and 89 y old; the average age was 70.2 y old; and the median age was 70 y old. The elderly account for the majority of the deaths: 35 patients were older than 65 y old, accounting for 70% of the total cases. Hubei has the highest disease density. Thirty-nine cases were reported in Hubei, accounting for 78%; 2 cases were reported in Henan; 2 cases were reported in Chongqing; 1 case was reported in Beijing; 1 case was reported in Shanghai; 1 case was reported in Hebei; 1 case was reported in Hainan; 1 case was reported in Sichuan; 1 case was reported in Hong Kong; and 1 case was reported in Philippines (Table 1 and Figure 1A,B).

Analysis of Clinical Characteristics
Symptom information of 45 cases was collected for review. The period of time from first symptom to death ranged between 4 and 41 days; the average time from morbidity to death was 14.5 days, with a median of 13 days. Among the cases, fever, cough, and dyspnea were the main symptoms, accounting for 82.2%, 55.6%, and 62.2%, respectively. Twelve patients had myalgia or fatigue, accounting for 26.7%. Three patients had digestive symptoms, accounting for 6.7%. Five patients had lethargy or coma, accounting for 11.1% (Table 1 and Figure 2). Thirty-seven patients had fever \( \geq 38°C \). Most of the patients were admitted to the intensive care unit in late stages of disease and showed critical clinical manifestations, such as respiratory failure and ARDS. Thirty-three cases also had other chronic fundamental diseases, accounting for 66.0% of the deaths, hypertension, chronic bronchitis, and diabetes being the most frequent, which accounted for 51.5%, 39.4%, and 21.2% of deaths, respectively (Table 1; Figure 1C-F).

Univariate Analysis
Univariate analysis was performed on gender, age, region, date of first symptom, and fundamental disease. We found that age was a factor that affects the average number of days from symptom onset until death. The time from the first symptom to death in the elderly older than 65 y old was shorter than that in other groups. The median number of days from the first symptom to death was 13, ranging from 4 days to 41 days. It tended to be shorter among people aged 65 and older (12 [interquartile range [IQR] = 6.75] days) than those younger than 65 (17 [IQR = 12.75] days; \( P = 0.046 \)) (Table 2; Figure 3A).

Correlation Analysis
Scatter plot and correlation analyses on age and the number of days from the first symptom to death were performed. We found that there was a correlation between age and average number of days until death, and the difference was statistically significant. The correlation coefficient was \(-0.40\), and the \( P \) value was 0.012 (Figure 3B).

### TABLE 1

| Value | N = 50 |
|-------|--------|
| Gender (%) |        |
| Male     | 35 (70.0) |
| Female   | 15 (30.0) |
| Age (median [IQR]) | 70 (65, 81) |
| Mean (SD)  | 70.18 (13.37) |
| <65      | 15 (30.0) |
| >65      | 35 (70.0) |
| Basic disease (%) |        |
| Yes      | 33 (66.0) |
| No       | 17 (34.0) |
| Fever (%) |        |
| Yes      | 37 (82.2) |
| No       | 8 (17.8)  |
| Cough (%) |        |
| Yes      | 25 (55.6) |
| No       | 20 (44.6) |
| Dyspnea (%) |      |
| Yes      | 28 (62.2) |
| No       | 17 (37.8) |
| Myalgia or fatigue (%) |    |
| Yes      | 3 (6.7)  |
| No       | 42 (93.3) |
| Digestive symptoms (%) |  |
| Yes      | 12 (26.7) |
| No       | 33 (73.3) |
| Lethargy or coma (%) |  |
| Yes      | 5 (11.1)  |
| No       | 40 (88.9) |
| Hypertension (%) |       |
| Yes      | 17 (51.5) |
| No       | 16 (48.5) |
| Diabetes (%) |     |
| Yes      | 13 (39.4) |
| No       | 20 (60.6) |
| Chronic bronchitis (%) |        |
| Yes      | 7 (21.2)  |
| No       | 26 (78.8) |
| The days of first symptom to death (median [IQR]) | 13 (11, 17) |
| Region (%) |        |
| Hubei    | 39 (78.0) |
| Other    | 11 (22.0) |
DISCUSSION

At the time of this writing, the outbreak of COVID-19 in Wuhan, other parts of China, and 24 other countries around the world has been occurring for nearly 2 months. According to the official announcement on February 10, 2020, 0:00 am, by the National Health Commission of the People's Republic of China, the number of confirmed cases of COVID-19 is 37,213, the death toll is 815, the current mortality is 2.2%.

Research to study this virus and the disease is ongoing. Peng Zhou et al. found that 79.5% of the sequence of SARS-CoV-2 is identical to that of SARS-CoV, and the virus has high homology with the bat coronavirus at the whole-genome level (96%). It is also proven that SARS-CoV-2 infects the body through the ACE2 receptor on cells, the same mechanism of infection as SARS-CoV. In clinical reports, De Chang et al., studying data from 13 patients, reported that the median age of patients was 34 y old. Most of the patients had a fever before admission, and the main symptoms were cough (46.3%) and upper airway congestion (61.5%).

Prof Chen et al. considered that, among the 99 patients they studied, approximately half had a history of contact with the Wuhan South China Seafood Market, and most of the patients were male, with an average age of 55.5 y (SD, 13.1), and 50 (51%) patients had another chronic disease before they acquired COVID-19. At present, we find that, although there are many published reports, few studies focused on death from COVID-19. One such study, by Wang et al., reported that deaths from SARS-CoV-2 pneumonia were mainly among the elderly. To learn more, we retrospectively collected data on 50 deaths caused by COVID-19 and carried out this analysis.

In this study, we observed that more males died than females, which was consistent with previous reports of MERS-CoV and SARS-CoV. In addition, most patients had different types of underlying chronic fundamental diseases, mainly cardiovascular diseases and chronic bronchitis, as well as diabetes, before contracting COVID-19, which is similar to the patients who contracted MERS. The main symptoms of fever, cough, respiratory discomfort, and a small proportion of gastrointestinal symptoms, were consistent with symptoms in patients with SARS and MERS. Our results showed that the clinical features of COVID-19 were similar to those of the previous epidemic’s coronavirus pneumonia and that it is more
likely to infect older men with chronic comorbidities, as a result of the weak immune function of these patients and stronger immune response in females caused by the additional X chromosome.\textsuperscript{22,23,25}

At the time of this writing, compared with SARS (9.2\%)\textsuperscript{26} and MERS (34.4\%),\textsuperscript{6} the mortality rate of COVID-19 is not as high, but the speed of transmission is faster, the infection is stronger, and the number of infected persons is higher.

### TABLE 2

| Parameter                        | Median (IQR)          | Kruskal-Wallis Test P-Value |
|----------------------------------|-----------------------|----------------------------|
| Gender (male vs female)          | 13 (11, 17)           | 0.987                      |
| Age (<65 vs >65)                 | 17 (11.75, 24.5)      | 0.044                      |
| Region (Hubei vs other)          | 14 (11, 20)           | 0.005                      |
| Fever (yes vs no)                | 13 (11, 17)           | 0.410                      |
| Cough (yes vs no)                | 14 (11, 20)           | 0.183                      |
| Dyspnea (yes vs no)              | 14 (11, 17)           | 0.313                      |
| Digestive symptoms (yes vs no)   | 15 (12, NA)           | 0.319                      |
| Myalgia or fatigue (yes vs no)   | 16 (11, 20.25)        | 0.155                      |
| Lethargy or coma (yes vs no)     | 12 (9.5, 18.25)       | 0.392                      |
| Basic disease (yes vs no)        | 13 (10, 17.75)        | 0.914                      |
| Hypertension (yes vs no)         | 14 (11, 17)           | 0.936                      |
| Diabetes (yes vs no)             | 12 (7, 20)            | 0.876                      |
| Chronic bronchitis (yes vs no)   | 13 (5, 15)            | 0.555                      |

### FIGURE 2

A-F, Comparison of the Influence of Clinical Features on the Time of First Symptom to Death (Days). Violin plots for (A) fever, (B) cough, (C) dyspnea, (D) digestive symptoms, (E) myalgia or fatigue, and (F) lethargy or coma.

[FIGURE 2 image]

Impact of Fundamental Diseases on Patients With COVID-19

Disaster Medicine and Public Health Preparedness

779
Therefore, we still need to be vigilant against this disease. We counted the number of days from the first symptom to death of 40 cases. The median survival time (in days) from onset to death was 13, the same as reported by Wang et al. Also, using single-factor analysis, we found that age was the key factor. Our study demonstrated that the time from the first symptom to death in the elderly (age > 65 y) was shorter than that of younger people (age ≤ 65 y), which is similar to that reported for MERS and SARS. On the other hand, other studies of patients with MERS found that patients with certain chronic diseases were more likely to die. However, our single-factor study did not find that these factors had statistical significance for the time. It may be that the sample size was too small. We suspect that people with these chronic diseases are more likely to become infected with COVID-19, but not to die. It also indirectly proves that this disease has a widespread, high infection rate, but low mortality compared with MERS and SARS. All in all, in the outbreak of COVID-19, we should pay attention to the health management and protection of the elderly.

Fortunately, academician Zhong Nanshan and his team from China released the guidelines for the prevention of COVID-19 among the elderly. The guidelines point out that the prevention of COVID-19 should be carried out according to age stratification, because the immunity of the elderly is relatively low. It is necessary to ensure the health of the elderly people. Also, the chronic diseases related to the elderly should be actively treated at the same time. We also call on everyone to pay special attention to the health management of the elderly, which is consistent with our conclusion.

There are several limitations to this study. The majority of cases are from Wuhan, Hubei Province, China. Second, only fatal cases were reported. It is preferable to add a considerable number of cases of survival. Finally, relevant laboratory test results and imaging data are lacking.

CONCLUSION

In our study, we found that most of the deaths were elderly men with chronic fundamental diseases, and their time of COVID-19 progression to death was shorter. We also demonstrated that older men were more likely to be infected with COVID-19 and the risk of death is positively correlated with age. All in all, we still need to pay more attention to the elderly patients who are infected with the SARS-CoV-2 virus.

About the Authors

Department of Neurosurgery, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China (Drs Yi Chen, Li, Pan); Department of Medical Oncology and Guangdong Key Laboratory of Liver Disease, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China (Dr Yo Chen); and Guangdong Medical University, Zhanjiang, Guangdong, China (Dr Ye).

Correspondence and reprint requests to Jun Pan, Department of Neurosurgery, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, Guangdong, China (e-mail: sjwpkj@163.com); or Yongjian Chen, Department of Medical Oncology and Guangdong Key Laboratory of Liver Disease, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, 510000, Guangdong, China (e-mail: chenyj326@mail2.sysu.edu.cn).

Conflict of interest

The authors have no conflicts of interest to disclose.

REFERENCES

1. Gorbalevya AE, Baker SC, Baric RS, et al. Severe acute respiratory syndrome-related coronavirus: the species and its viruses - a statement of the coronavirus study group. Nat Microbiol. 2020. doi: 10.1038/s41564-020-0695-z
2. Hui DS, Azhar EI, Madani TA, et al. The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health - the latest 2019 novel coronavirus outbreak in Wuhan, China. Int J Infect Dis. 2020;91:264-266.

3. World Health Organization. novel coronavirus (2019-ncov) situation reports-22. February 11, 2020. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports. Accessed May 6, 2020.

4. Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020. doi: 10.1001/Jama.2020.1585

5. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507-513.

6. Lee PI, Hsueh PR. Emerging threats from zoonotic coronaviruses-from SARS to 2019-nCoV. J Microbiol Immunol Infect. 2020. doi: 10.1016/j.mii.2020.02.001

7. Wuhan Municipal Health Commission. Released January 16, 2020. http://wjw.Wuhan.Gov.Cn/front/web/showdetail/20200116090857.

8. Wuhan Municipal Health Commission. Released on January 21, 2020. http://wjw.Wuhan.Gov.Cn/front/web/showdetail/20200121090833.

9. National health commission of the people’s republic of china. Released on January 23, 2020. http://www.Nhc.Gov.Cn/yjb/s3578/202001/5d19af46f3154b9f03e328918ed2e3c8a.Shtml

10. Public Address of Hebei Radio and Tv Station of china. Released on January 25, 2020. https://mp.Weixin.Qq.Com/s/ywotmsrbl9jui_wF084ug.

11. Nanyang Municipal Health Commission. Released on January 27, 2020. http://nyws.Nanyang.Gov.Cn/gd/r/357645.Htm.

12. Xinhuanet. New-type coronavirus causes pneumonia in Wuhan: Expert. Released on January 30, 2020. http://www.Sc.Xinhuanet.Com/content/2020-01/30/c_1125512060.Htm.

13. China Central Television. Released on February 2, 2020. http://news.Cctv.Com/2020/02/02/artiviyzud67kce5ycyjikq/202002.Htm

14. Liaison office of the central people’s government in the hong kong special administrative region. Released on February 5, 2020. http://www.Locpg.Gov.Cn/jdht/2020-02/05/c_1210462159.Htm.

15. National Health Commission of the People’s Republic of China. http://www.Nhc.Gov.Cn.

16. Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270-273.

17. Chang, Lin M, Wei L, et al. Epidemiologic and clinical characteristics of novel coronavirus infections involving 13 patients outside Wuhan, China. JAMA. 2020. doi: 10.1001/jama.2020.1623

18. Wang W, Tang J, Wei F. Updated understanding of the outbreak of 2019 novel coronavirus (2019-nCoV) in Wuhan, China. J Med Virol. 2020;92(4):441-447.

19. Habib AMG, Ali MAE, Zouaoui BR, et al. Clinical outcomes among hospital patients with Middle East Respiratory Syndrome Coronavirus (MERS-CoV) infection. BMC Infect Dis. 2019;19(1):870.

20. Leung GM, Hedley AJ, Ho LM, et al. The epidemiology of severe acute respiratory syndrome in the 2003 Hong Kong epidemic: an analysis of all 1755 patients. Ann Intern Med. 2004;141(9):662-673.

21. Alraadadi BM, Watson JT, Almarashi A, et al. Risk factors for primary Middle East respiratory syndrome coronavirus illness in humans, Saudi Arabia, 2014. Emerg Infect Dis. 2016;22(1):49-55.

22. Assiri A, Al-Tawfiq JA, Al-Kabeeah AA, et al. Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East Respiratory Syndrome Coronavirus Disease from Saudi Arabia: a descriptive study. Lancet Infect Dis. 2013;13(9):752-761.

23. Nassar MS, Bakheebah MA, Meo SA, et al. Middle East Respiratory Syndrome Coronavirus (MERS-CoV) infection: epidemiology, pathogenesis and clinical characteristics. Eur Rev Med Pharmacol Sci. 2018;22(15):4956-4961.

24. Booth CM, Matukas LM, Tomlinson GA, et al. Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. JAMA. 2003;289(21):2801-2809.

25. Jaillon S, Berthenet K, Garlanda C. Sexual dimorphism in innate immunity. Clin Rev Allerg Immunol. 2019;56(3):308-321.

26. World Health Organization. Summary of probable SARS cases with onset of illness from 1 november 2002 to 31 july 2003 (based on data as of the December 31, 2003). http://www.Who.Int/csr/sars/country/table2004_04_21/en/index.Html. Accessed May 6, 2020.

27. Donnelly CA, Ghani AC, Leung GM, et al. Epidemiological determinants of spread of causal agent of severe acute respiratory syndrome in Hong Kong. Lancet. 2003;361(9371):1761-1766.

28. Majundar MS, Klaberg SA, Mekaru SR, et al. Mortality risk factors for Middle East respiratory syndrome outbreak, South Korea, 2015. Emerg Infect Dis. 2015;21(11):2088-2090.

29. China Central Television. Released on February 5, 2020. http://news.Cnt.Cn/xiaozhi/c4981f99-e083-393c-6b4a-7d37c5f28b5c.Html?Ivak_ssa=1023197a. Accessed May 6, 2020.